Commissioner and Commission Staff Public Statements and Letters

Displaying 121 - 140 of 350

Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs

LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Dr. Gary Arbuckle and Ms. Amy Freeze, and


Mary K. Engle